Caricamento...
A single arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma (RCC)
BACKGROUND: Everolimus ,an oral inhibitor of mammalian target of rapamycin (mTOR), and sunitinib, an oral inhibitor of VEGF/PDGF receptor tyrosine kinase signaling, have both been shown to provide clinical benefit in patients with advanced RCC. We sought to determine the safety and efficacy of combi...
Salvato in:
| Pubblicato in: | Clin Genitourin Cancer |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4754968/ https://ncbi.nlm.nih.gov/pubmed/26174223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.12.011 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|